ChiCTR2300069088 版本V1.1 版本创建时间2023/07/07 22:15:26 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300069088 

最近更新日期:

Date of Last Refreshed on:

2023-03-06 17:13:27 

注册时间:

Date of Registration:

2023-03-06 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

头端可弯曲负压输尿管软镜鞘在输尿管软镜碎石中的应用研究

Public title:

Study on the application of head flexible negative pressure ureteral flexible sheath in flexible ureteroscopic lithotripsy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

头端可弯曲负压输尿管软镜鞘在输尿管软镜碎石中的应用研究

Scientific title:

Study on the application of head flexible negative pressure ureteral flexible sheath in flexible ureteroscopic lithotripsy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

申忠华 

研究负责人:

刘春雨 

Applicant:

Shen Zhonghua 

Study leader:

Liu Chunyu 

申请注册联系人电话:

Applicant telephone:

18103159380

研究负责人电话:

Study leader's telephone:

13821985158

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yjs_shenzhonghua@tmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

prof_liucy@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

天津市河西区平江道23号天津医科大学第二医院

研究负责人通讯地址:

天津市河西区平江道23号天津医科大学第二医院

Applicant address:

The Second Hospital of?Tianjin Medical University, 23 Pingjiang Road, Hexi District, Tianjin

Study leader's address:

The Second Hospital of?Tianjin Medical University, 23 Pingjiang Road, Hexi District, Tianjin

申请注册联系人邮政编码:

Applicant postcode:

300000

研究负责人邮政编码:

Study leader's postcode:

300000

申请人所在单位:

天津医科大学第二医院

Applicant's institution:

The Second Hospital of?Tianjin Medical University

研究负责人所在单位:

天津医科大学第二医院

Affiliation of the Leader:

The Second Hospital of?Tianjin Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

科审[2023]第(004)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

天津医科大学第二医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the Second Hospital of Tianjin Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-02-28 00:00:00

伦理委员会联系人:

彭诚

Contact Name of the ethic committee:

Peng Cheng

伦理委员会联系地址:

天津市河西区平江道23号

Contact Address of the ethic committee:

No.23, Pingjiang Road, Hexi District, Tianjin

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 22 88328108

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津医科大学第二医院

Primary sponsor:

The Second Hospital of Tianjin Medical University

研究实施负责(组长)单位地址:

天津市河西区平江道23号

Primary sponsor's address:

No.23, Pingjiang Road, Hexi District, Tianjin

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津市

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津医科大学第二医院

具体地址:

天津市河西区平江道23号

Institution
hospital:

The Second Hospital of Tianjin Medical University

Address:

No.23, Pingjiang Road, Hexi District, Tianjin

经费或物资来源:

自筹

Source(s) of funding:

self-financing

Target disease:

Calculus of upper urinary tract

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1、探讨头端可弯曲负压输尿管软镜鞘在输尿管软镜碎石术中的可行性及安全性; 2、评价头端可弯曲负压输尿管软镜鞘在输尿管软镜碎石中的应用价值。  

Objectives of Study:

1,To investigate the feasibility and safety of the head flexible negative pressure ureteral flexible sheath in ureteral flexible lithotripsy. 2,To evaluate the value of the head flexible negative pressure ureteral flexible sheath in ureteral flexible lithotripsy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1)入组前签署书面知情同意书;
2)年龄>18岁,男女均可;
3)输尿管上段或肾结石直径小于2.0cm,或多发结石最大径小于2.0cm,经尿路平片、超声或CT等影像学检查诊断明确;
4)无泌尿系肿瘤、无明显输尿管狭窄、无泌尿系发育畸形;
5)受试者自愿加入本研究,依从性好,配合安全性和生存期随访。

Inclusion criteria

1) Signed written informed consent prior to enrollment.
2) Age > 18 years, both sexes.
3)unilateral upper ureteral or renal stones less than 2.0 cm in diameter, or multiple stones with a diameter less than 2.0 cm, with a clear diagnosis by imaging such as urethral plain film, ultrasound or CT.
4) No urological tumor, no significant ureteral stenosis, and no developmental malformation of the urinary tract.
5)Subjects voluntarily enrolled in this study, with good compliance and cooperation with safety and survival follow-up.
Patients with any of the following cannot be enrolled in this study
1) Severe preoperative urinary tract infection not controlled.
2)Patients with severe hydronephrosis and renal insufficiency, large stone size requiring multiple lithotripsy, and isolated kidney.
3) pregnancy, coagulation abnormalities (PT>16s, APTT>43s, TT>21s, Fbg>2g/L), severe cardiac, cerebral and pulmonary diseases and contraindications to surgery.
4)Ureteral calculi with severe impaction that cannot be displaced to the kidney.
5)Did not sign the written informed consent.
6)Any others which are not suitable for entering the study

排除标准:

1)术前严重尿路感染未控制;
2)严重肾积水及肾功能不全、结石体积较大需要多次碎石、孤立肾的患者;
3)妊娠,凝血异常(PT>16s、APTT>43s、TT>21s、Fbg>2g/L)、有严重心脑肺疾病及手术禁忌症者;
4)输尿管结石嵌顿严重不能移位至肾脏者;
5)受试者未签署知情同意书;
6)其他任何不适宜进入该研究的患者。

Exclusion criteria:

1) The subject or his or her legal representative requests to withdraw.
2) Continued participation in the study would be detrimental to their health.
3) The subject's pregnancy or loss of visit.
4) Withdrawal from the study is deemed necessary by the investigator.
5) All withdrawals should be followed up according to the study protocol and the results recorded, unless the patient 6)withdraws informed consent and refuses to be followed up.

研究实施时间:

Study execute time:

From 2023-03-06 00:00:00 To 2024-07-06 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-03-06 00:00:00 To 2024-07-06 00:00:00  

干预措施:

Interventions:

组别:

可弯鞘组

样本量:

252

Group:

head flexible group

Sample size:

干预措施:

应用可弯鞘

干预措施代码:

Intervention:

application of head flexible group

Intervention code:

组别:

普通鞘组

样本量:

252

Group:

common group

Sample size:

干预措施:

应用普通鞘

干预措施代码:

Intervention:

application of common sheath group

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

天津市 

市(区县):

 

Country:

China 

Province:

Tinajin 

City:

 

单位(医院):

天津医科大学第二医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Hospital of Tianjin Medical University

Level of the institution:

Third-level grade A hospital

测量指标:

Outcomes:

指标中文名:

即刻清石率

指标类型:

主要指标

Outcome:

immediately stone free rates

Type:

Primary indicator

测量时间点:

术后第1天

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后3月清石率

指标类型:

主要指标

Outcome:

3th Month stone free rates

Type:

Primary indicator

测量时间点:

术后3月

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后并发症

指标类型:

次要指标

Outcome:

Postoperative complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

感染发生情况

指标类型:

次要指标

Outcome:

incidence of postoperative SIRS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院费用

指标类型:

次要指标

Outcome:

hospitalization expenses

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者采用随机数表进行随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table was used for random grouping

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

单盲

Blinding:

single blind

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

待实验结束后以论文的形式进行展示

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Show in the form of paper after the experiment

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集采用病例记录表(CRF)、电子采集和管理系统(EDC)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data were collected using the case record form and electronic data capture.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-03-06 17:13:08